ARMO BioSciences (ARMO) IPO Opens Up 65%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
ARMO BioSciences Announces Pricing of Initial Public Offering
January 25, 2018 9:09 PM ESTREDWOOD CITY, Calif., Jan. 25, 2018 /PRNewswire/ -- ARMO BioSciences, Inc. ("ARMO"), a late-stage immuno-oncology company, today announced the pricing of its initial public offering of 7,529,412 shares of its common stock at a price to the public of $17.00 per share for total gross proceeds of approximately $128.0 million. The shares are expected to begin trading on The Nasdaq Global Select Market on January 26, 2018 under the ticker symbol "ARMO." The offering is expected to close on January 30, 2018, subject to customary closing conditions.
In addition, ARMO has granted the underwriters a 30-day option to purchase up to an additional... More
